Reviewer’s report

Title: Network Meta-analysis and Cost per Responder of Targeted Immunomodulators in the Treatment of Active Psoriatic Arthritis

Version: 0  Date: 04 Dec 2017

Reviewer: Fabio Massimo Perrotta

Reviewer's report:

This is an interesting manuscript that assessed the comparative efficacy of different treatments available for Psoriatic Arthritis. To date, no head-to-head studies were performed to determine the most efficacy treatment in Psoriatic Arthritis between the different biologic and small molecules drugs, so network analysis that indirectly compare different clinical trial could be useful. The study is well written and methodologically well performed. I have only some suggestions to improve the quality of the manuscript.

1) Since the efficacy of biologic and small molecules could be improved by the association with classic synthetic DMARDs, it would be useful to verify how many patients in the different clinical trials were treated with classic DMARDs

2) The recent Treat-to-target recommendations for PsA introduced the concept of remission or low disease activity as the target of therapy. If available in the different trials, it would be useful to compare even the percentage of patients achieving minimal disease activity.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.